Member Info for Sheepy57

Yeah why not? I want to see share price to stabilize first before going for it. Doesn't matter if its around 90p or 110p.

It is so low now. I'm nearly ready to dip a toe.

Stemcells Inc grows on Nasdaq 800% today.

It will be extremaly difficult to deliver for TRAK to justify finncap forecast of 425p confirmed today.

Big volume today, have I missed any news?

That's because some of the earnings from new contracts may not be booked in within this financial year as previously thought. Fundamentals stay the same but investors need more patience. Whats more some people are nervouse about potential of US vote recounting. I'll be observing this share for some time. It could still be looking for the bottom.

There might be another Skyscanner among fund's rising stars. I think that in few years MERC will be big thanks to investing in British new technologies. The potential is limitless but the share price doesn't reflect that yet.

Drug device designer Vectura may be receive a sales boost from changes in treatment guidelines for chronic obstructive pulmonary disease (COPD). The new guidelines favour types of inhaler like the Ultibro that Vectura has developed in partnership with Swiss drugs giant Novartis, reported the Sunday Telegraph.

Something is brewing behind the scene.I've got the feeling that the share will soon go over the moon.

Couldn't wait any longer and topped up.Just in case it reached the bottom of a slide.

Two selling trades 200.000 each at 388.3p went through.It's still under pressure.

Share price resumed its downward path. Yesterdays 6m+ volume only gave the short break.With such significant drop we saw recently it would not last long I think.

It may be the change of sentiment on a bond market that influences recent drop in share price. Market may be preparing to a FED interest rate hike in the near future and then possibly European Central Bank follow suit.

It is not a concern but a buying opportunity although I will try to wait a little bit longer for a top up.

Group and portfolio developments · Successful integration of Enterprise Ventures Group Limited ("EV") into the Group · £5.7million invested in nine portfolio companies of which three are new 'Emerging Stars', taking total invested since IPO to £30.0million o Two of three new Emerging Stars (Concepta plc and sureCore) originated from EV's managed funds, reflecting the benefit of enlarged pipeline of direct investment opportunities post EV acquisition · Third party funds: £8.6million raised and £11.5million invested into 58 companies in the period. Total managed funds of circa £228.0million at period end · Good progress across the portfolio. Notable highlights: o Portfolio company Concepta plc admitted to trading on AIM in July 2016 o nDreams appointed by Google to make apps and experiences for Daydream, its virtual reality ("VR") mobile platform, together with the successful launch of nDreams' VR game, The Assembly Financial highlights · Investment portfolio fair value up by £8.5million or 22% to £46.6million as a result of £5.7million of net new capital invested and £2.8million of net upward fair value movements · Net assets of £81.3million (2015: £80.2million) · Cash and short-term liquidity investments of £24.0million (2015: £48.5million) · Post-tax profit of £1.1million (2015: loss of £0.8million) Post period end · Circa £1.7million invested post period end, including £1.0million into Oxford Genetics and £0.5million into nDreams · Oxford Genetics secured a £1.7million grant to fund further expansion

Do you hear the sigh made by AEK? If Trump wins we may see mid 300p once again. I'm prepared to top up.

Interim results for the six months ended on 30 Sept 2016 will be announced on Monday 28 November.

According to Reuters Vectura is on a lookout for deals to build specialised lung drug business. Next target : established US company.

It's not even 10% down from the year high. No need to contemplate the fall.

Short sellers got active? Looking forward to top up when the sp slide a little bit further.